Critical Survey: electroCore (NASDAQ:ECOR) and Clarus Therapeutics (OTCMKTS:CRXTQ)

Clarus Therapeutics (OTCMKTS:CRXTQ) and electroCore (NASDAQ:ECOR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Profitability

This table compares Clarus Therapeutics and electroCore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clarus Therapeutics	N/A	N/A	N/A
electroCore	-47.46%	-447.87%	-73.83%

Valuation & Earnings

This table compares Clarus Therapeutics and electroCore”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A
electroCore	$25.18 million	1.79	-$11.89 million	($1.71)	-3.29

Clarus Therapeutics has higher earnings, but lower revenue than electroCore.

Insider and Institutional Ownership

26.7% of electroCore shares are held by institutional investors. 5.3% of Clarus Therapeutics shares are held by insiders. Comparatively, 13.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Clarus Therapeutics and electroCore, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clarus Therapeutics	0	0	0	0	0.00
electroCore	1	0	2	0	2.33

electroCore has a consensus target price of $25.50, indicating a potential upside of 352.93%. Given electroCore’s stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Clarus Therapeutics.

Summary

electroCore beats Clarus Therapeutics on 6 of the 9 factors compared between the two stocks.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

About electroCore

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.